KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Cash from Operations (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Cash from Operations for 15 consecutive years, with 60678000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 269.87% year-over-year to 60678000.0, compared with a TTM value of 37784000.0 through Dec 2025, up 115.91%, and an annual FY2025 reading of 37784000.0, up 115.91% over the prior year.
  • Cash from Operations was 60678000.0 for Q4 2025 at Travere Therapeutics, up from 14317000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 60678000.0 in Q4 2025 and bottomed at 118902000.0 in Q1 2024.
  • Average Cash from Operations over 5 years is 37112050.0, with a median of 38576000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations surged 376.07% in 2021, then plummeted 785.85% in 2023.
  • Year by year, Cash from Operations stood at 88323000.0 in 2021, then soared by 97.57% to 2149000.0 in 2022, then tumbled by 785.85% to 19037000.0 in 2023, then crashed by 87.63% to 35720000.0 in 2024, then skyrocketed by 269.87% to 60678000.0 in 2025.
  • Business Quant data shows Cash from Operations for TVTX at 60678000.0 in Q4 2025, 14317000.0 in Q3 2025, and 4983000.0 in Q2 2025.